Irinotecan 盐酸盐

• 产品号: I1406
• CAS号: 100286-90-6
• 分子式: C33H39ClN4O6
• 分子量: 623.13896

产品别名

• 标题: Irinotecan hydrochloride
• IUPAC标准名: (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^2,^1^1.0^4,^9.0^1^5,^2^0]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate hydrochloride
• IUPAC传统名: (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^2,^1^1.0^4,^9.0^1^5,^2^0]henicosa-1(21),2,4,6,8,10,15(20)-heptaen-7-yl 4-(piperidin-1-yl)piperidine-1-carboxylate hydrochloride
• 别名: CPT-11; [1,4′-Bipiperidine]-1′-carboxylic acid; (S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester

产品登记号

• MDL号: MFCD01862255
• CAS号: 100286-90-6

产品性质

• Empirical Formula (Hill Notation): C33H38N4O6 · HCl
• 相关基因信息: human ... TOP1(7150)
• GHS警示词: Warning
• GHS危险声明: H302
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 个人保护装置: dust mask type N95 (US), Eyeshields, Gloves
• 危险公开号: 22
• RTECS编号: DW1061000
• 保存温度: 2-8°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
The anticancer agent, irinotecan, is a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I. Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1 (UGT1A1). It proves useful in radiation treatment of tumors by sensitizing tissue to radiation damage.1
The anticancer agent, irinotecan, is a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I. Its action is terminated by glucuronidation by UDP glucuronosyl transferase.

详细说明 (简体中文)

Biochem/physiol Actions
The anticancer agent, irinotecan, is a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I. Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1 (UGT1A1). It proves useful in radiation treatment of tumors by sensitizing tissue to radiation damage.1
The anticancer agent, irinotecan, is a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), a potent inhibitor of DNA topoisomerase I. Its action is terminated by glucuronidation by UDP glucuronosyl transferase.